News Search Results
Jan 30, 2024, 06:30 ET Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
Partner and Director of Clinical Research, Retina Macula Institute of Arizona, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine, Phoenix, AZ Date and time:
More news about: Kodiak Sciences Inc.
Jan 26, 2024, 10:30 ET Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.
areas Based on therapeutic area, the regenerative medicine market is classified into oncology, neurology, musculoskeletal disorders, ophthalmology, cardiovascular diseases, dermatology & wound care and other applications. In 2022, the musculoskeletal disorders segment accounted for the
More news about: MarketsandMarkets
Jan 26, 2024, 07:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT™), through which APP13007 was developed, improves the dissolution
More news about: Formosa Pharmaceuticals Inc.
Jan 25, 2024, 03:30 ET Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
diseases within ophthalmology, today announces the start of a phase 1b/2a clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular edema (DME). Breye is developing novel, oral ophthalmology drugs to address
More news about: Breye Therapeutics
Jan 24, 2024, 09:00 ET Ocutrx Unveils 3D Breakthrough, Enhancing Spine Surgery with Ergonomically Designed DigiLoupes Technology
featuring the stand-alone DigiLoupe™, represents a major development over traditional loupes. The ORLenz, already under clinical assessments for ophthalmology, is making considerable progress in spine surgery applications. Dr. Leonel Hunt, a highly esteemed spine specialist
More news about: Ocutrx
Jan 24, 2024, 08:00 ET Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
lamp examination, fundoscopy, and optical coherence tomography. Withhold or permanently discontinue BALVERSA® based on severity and/or ophthalmology exam findings. Hyperphosphatemia and Soft Tissue Mineralization – BALVERSA® can cause hyperphosphatemia leading to soft
More news about: Johnson & Johnson
Jan 23, 2024, 08:08 ET BroadcastMed Launches New Platform for Vision Portfolio of Products
think the changes will be appreciated by everyone!" said Peter K. Kaiser, MD, Professor of Ophthalmology, Chaney Family Endowed Chair in Ophthalmology Research. BroadcastMed, together with 424 Capital, a growth capital partner, acquired PentaVision in August of 2022
More news about: BroadcastMed
Jan 23, 2024, 08:00 ET Covenant High Plains Surgery Center awarded "Best of the West" Outpatient Surgery Center third year in a row
well as advanced surgical treatment options in bariatrics, ENT, general surgery, GI, gynecology, interventional pain, neuro & spine surgery, ophthalmology, orthopedics, maxillofacial, plastic & reconstructive surgery, podiatry, and urology to patients from Texas,
More news about: Covenant High Plains Surgery Center
Jan 23, 2024, 05:45 ET Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2024-2030, Featuring Glaukos, Johnson & Johnson Vision, AbbVie, Corza Ophthalmology, Lumenis & Ziemer Ophthalmic Systems
Landscape8.1. Key Company Profiles GlaukosJohnson & Johnson VisionAbbVieCorza OphthalmologyCarl Zeiss MeditecKatalyst SurgicalLumenisZiemer Ophthalmic SystemsIridex.For more information
More news about: Research and Markets
Jan 22, 2024, 06:52 ET Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Jan 21, 2024, 23:35 ET USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and collaborations are notably driving market growth-17,000+ Technavio Research Reports
Download a Free Sample Report Based on the Application, the market is classified into oncology and ophthalmology. The market share growth of the oncology segment will be significant during the forecast period. In the field of oncology, VEGF inhibitors
More news about: Technavio
Jan 19, 2024, 15:21 ET U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
examination, fundoscopy, and optical coherence tomography. Withhold or permanently discontinue BALVERSA® based on severity and/or ophthalmology exam findings [see Dosage and Administration (2.3)]. Hyperphosphatemia and Soft Tissue Mineralization – BALVERSA®
More news about: Johnson & Johnson
Jan 18, 2024, 16:20 ET CU Anschutz Announces Awardees for the Anschutz Acceleration Initiative
Jayashree Kalpathy-Cramer, PhD | Professor, Ophthalmology Kalpathy-Cramer and team are developing a multidisciplinary project by bringing AI-assisted ophthalmic imaging outside of ophthalmology to improve patient health and clinical outcomes, meet quality metrics
More news about: University of Colorado Anschutz Medical Campus
Jan 17, 2024, 16:30 ET Taro Announces Merger Agreement with Sun Pharma
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Jan 17, 2024, 16:30 ET Taro Announces Merger Agreement with Sun Pharma
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Jan 16, 2024, 13:04 ET Global EYLEA Drug Market Size to Surpass US$ 14.30 Billion by 2030 | Exhibiting a CAGR of 7.2% : CoherentMI
treatment option for these eye disorders, which is driving its adoption in the market. Secondly, technological advancements in the field of ophthalmology are also contributing to the growth of the market. The development of novel and more efficient drug delivery systems and the introduction of advanced
More news about: Coherent Market Insights
Jan 16, 2024, 10:10 ET THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS
foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery. The well-rounded program includes keynote presentations and ground-breaking sessions on the latest techniques
More news about: American Academy of Cosmetic Surgery (AACS)
Jan 16, 2024, 10:00 ET Tarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial of TRS01 Ophthalmic Solution for the Treatment of Non-infectious Uveitis including Uveitic Glaucoma
devastation," stated Prof. Palestine. Director, Center for Ocular Inflammation at the University of Colorado Department of Ophthalmology. "Presently, there are no FDA-approved, steroid-free topical medications for this condition. An eye drop product that effectively resolves inflammation
More news about: Tarsier Pharma
Jan 16, 2024, 07:00 ET InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024, Expects Q4 Revenue Between $126.0M-$126.5M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode LTD
Jan 16, 2024, 07:00 ET WELL Health Provides Business Update Demonstrating Focus on Profitable and Capital Efficient Growth
trusted clinic enhances WELL's network with a range of specialized services including family practice, internal medicine, obstetrics/gynecology, ophthalmology, and more. With over 40 skilled physicians, Manitoba Clinic broadens the depth and breadth of WELL's medical expertise and extends its reach to
More news about: WELL Health Technologies Corp.
Jan 15, 2024, 10:30 ET Ophthalmic Equipment Market Worth $88.5 Billion | MarketsandMarkets™
https://www.marketsandmarkets.com/ResearchInsight/ophthalmology-devices-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content
More news about: MarketsandMarkets
Jan 12, 2024, 17:15 ET F. Hoffmann-La Roche Ltd Digital Transformation Strategy Analysis Report 2023: Technology Focus, Initiatives, Roche Venture Fund, Investments, Acquisitions, Partnerships, ICT Budget and Contracts
that develops drugs and diagnostics devices for treating diseases. It provides medicines and diagnostics for oncology, immunology, neuroscience, ophthalmology, infectious diseases, respiratory, and other areas. The company also provides in-vitro diagnostics, tissue-based cancer diagnostics, and diabetes
More news about: Research and Markets
Jan 12, 2024, 14:06 ET Glaucoma Research Foundation to Celebrate Research Pioneers, Patient Advocates, and Visionary Donors at Annual Gala
for people around the world. Dr. Munnerlyn is recognized internationally as a pioneering research engineer in the field of optics and lasers in ophthalmology. He designed the first excimer laser for laser vision correction eye surgery in 1985, and he founded VISX, which was once the world's largest manufacturer
More news about: Glaucoma Research Foundation
Jan 11, 2024, 07:00 ET U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
legacy of innovation to meet the evolving needs of refractive surgeons," said Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "As part of the ZEISS Medical Ecosystem, this next generation
More news about: Carl Zeiss Meditec AG
Jan 11, 2024, 07:00 ET U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
legacy of innovation to meet the evolving needs of refractive surgeons," said Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "As part of the ZEISS Medical Ecosystem, this next generation
More news about: Carl Zeiss Meditec AG